Urinary loss of immunoglobulin G anti-F(ab')2 and anti-DNA antibody in systemic lupus erythematosus nephritis

Journal of Laboratory and Clinical Medicine

Volumn 132, Issue 3, 1998, Pages 210-222

  Williams Jr , Ralph C ^a   Malone, Christine C ^b   Miller, R Tyler ^b   Silvestris, Francesco ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 13144254194     PISSN: 00222143     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-2143(98)90170-6     Document Type: Article

References (31)

1. Tan EM. Autoantibodies to nuclear antigens (ANA): their immunobiology and medicine. Adv Immunol 1982;33:167-240.
2. Asherson RA, Baguley E, Pal C, Hughes GRV. Antiphospholipid syndrome: five-year follow-up. Ann Rheum Dis 1991; 50:805-10.
3. Williams GW, Bluestein HG, Steinberg AD. Brain-reactive lymphocytotoxic antibody in the cerebrospinal fluid of patients with systemic lupus erythematosus: correlation with central nervous system involvement. Clin Immunol Immunopathol 1981;18:126-32.
4. Hanson VG, Horowitz M, Rosenbluth D, Spiera H, Puszkin S. Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50 KD neuronal membrane protein. J Exp Med 1992;176:565-73.
5. Bresnihan B, Jasin HE. Suppressor function of peripheral blood mononuclear cells in individuals and in patients with systemic lupus erythematosus. J Clin Invest 1977;59:106-16.
6. Sakane T, Steinberg AD, Green I. Studies of immune functions of patients with systemic lupus erythematosus I dysfunction of suppressor T cell activity related to impaired generation of, rather than response to, suppressor cells. Arthritis Rheum 1978;21:657-64.
7. Krakauer RS, Clough JD, Alexander T, Sundeen J, Sauder DN. Suppressor cell defect in SLE: relationship to native DNA binding. Clin Exp Immunol 1980;40:72-6.
8. Metsarinne KP, Nordstrom DCE, Kontinnen YT, Teppo A-M, Fyhrquist FY. Plasma interleukin-6 and renin substrate in reactive arthritis, rheumatoid arthritis, and systemic lupus erythematosus. Rheumatol Int 1992;12:93-6.
9. Guerne PA, Zuraw BL, Vaughan JH, Carson DA, Lotz M. Synovium as a source of interleukin-6 in vitro: contribution to local and systemic manifestations of arthritis. J Clin Invest 1989;83:585-92.
10. Arend WP, Dayer J-M. Naturally occurring inhibitors of cytokines, immunopharmacology of joints and connective tissue. Davis ME, Dingle JT, editors. London: Academic Press; 1994.
11. Jerne NK. In: Porter R, Knight J, editors. Ontogeny of acquired immunity. Ciba Foundation Symposium. New Series 5. Amsterdam: Associated Scientific Publishers; 1972.
12. Jerne NK. Towards a network theory of the immune system. Ann Immun (Inst Pasteur) 1974;125C:273.
13. Abdou NI, Wall H, Lindsley HB, Halsey JF, Suzuki T. Network theory in autoimmunity: in vitro suppression of serum anti-DNA antibody binding to DNA by anti-idiotypic antibody in systemic lupus erythematosus. J Clin Invest 1981; 67:1297-304.
14. Abdou NI, Wall H, Clancy J Jr. The network theory in autoimmunity: in vitro modulation of DNA-binding cells by anti-idiotypic antibody present in inactive lupus sera. J Clin Immunol 1981;1:234-40.
15. 2 antibodies and possible immunologic control mechanisms in systemic lupus. Arthritis Rheum 1984;27:1387-96.
16. 2 antibodies in relatives of patients with systemic lupus erythematosus. Clin Exp Immunol 1985;60:329-38.
17. 2 system. J Rheumatol 1995;22:1075-80.
18. 2 antibody cross reacts with DNA and other nuclear antigens. Arthritis Rheum 1997;40:109-23.
19. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Roth-field NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Urowitz MB, Gladman DD, Tozman ECS, Goldsmith. The lupus activity criteria count (LACC). J Rheumatol 1984; 11:783-7.
21. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989;32:1107-18.
22. Devey ME, Bleasdale K, Lee S, Rath S. Determination of the functional affintity of IgG1 and IgG4 antibodies to tetanus toxoid by isotype-specific solid-phase assays. J Immunol Methods 1988;106:119-25.
23. Goldblatt D, vanEtten L, van Milligen FJ, Aalberse RC, Turner MW. The role of pH in modified ELISA procedures used for the estimation of functional antibody affinity. J Immunol Methods 1993;166:281-5.
24. Coplon NS, Diskin CJ, Peterson J, Swenson RS. The long term clinic course of systemic lupus erythematosus in end-stage renal disease. N Engl J Med 1983;208:186-90.
25. Kimberly RP, Lockshin MD, Sherman RL, Beary JF, Mouradian J, Cheigh JS. End-stage lupus nephritis. Clinical course to and outcome on dialysis: experience with 39 patients. Medicine 1981;60:277-87.
26. Correia P, Cameron JS, Ogg CS, Williams DG, Bewick M, Hicks JA. End-stage renal failure in systemic lupus erythematosus with nephritis. Clin Nephrol 1984;22:293-302.
27. Myers BD, Guasch A. Selectivity of the glomerular filtration barrier in healthy and nephrotic humans. Am J Nephrol 1993;13:311-7.
28. Hanson LA, Tan EM. Characterization of antibodies in human urine. J Clin Invest 1965;44:703-15.
29. Epstein WV, Grausz H. Favorable outcome in diffuse proliferative glomerulonephritis of systemic lupus erythematosus. Arthritis Rheum 1974;17:129-42.
30. Meryhew NL, Messner RP, Tan EG. Urinary excretion of antinuclear antibodies. J Rheumatology 1983;10:913-9.
31. Ramjee G, Coovadia HM, Adhikari M. Direct and indirect tests of pore size and charge selectivity in nephrotic syndrome. J Lab Clin Med 1996;127:195-9.